186 related articles for article (PubMed ID: 34469285)
1. Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA.
Samore MH; Looney A; Orleans B; Greene T; Seegert N; Delgado JC; Presson A; Zhang C; Ying J; Zhang Y; Shen J; Slev P; Gaulin M; Yang MJ; Pavia AT; Alder SC
Emerg Infect Dis; 2021 Nov; 27(11):2786-2794. PubMed ID: 34469285
[TBL] [Abstract][Full Text] [Related]
2. Changes in Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Over Time in 10 Sites in the United States, March-August, 2020.
Lim T; Delorey M; Bestul N; Johannson MA; Reed C; Hall AJ; Fry AM; Edens C; Semenova V; Li H; Browning P; Desai R; Epperson M; Jia T; Thornburg NJ; Schiffer J; Havers FP
Clin Infect Dis; 2021 Nov; 73(10):1831-1839. PubMed ID: 33639620
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
[TBL] [Abstract][Full Text] [Related]
5. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study.
Pallett SJC; Rayment M; Patel A; Fitzgerald-Smith SAM; Denny SJ; Charani E; Mai AL; Gilmour KC; Hatcher J; Scott C; Randell P; Mughal N; Jones R; Moore LSP; Davies GW
Lancet Respir Med; 2020 Sep; 8(9):885-894. PubMed ID: 32717210
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19).
Kislaya I; Gonçalves P; Gómez V; Gaio V; Roquette R; Barreto M; Sousa-Uva M; Torres AR; Santos J; Matos R; Manita C; Almeida Santos J; Soeiro S; de Sousa R; Costa I; Verdasca N; Guiomar R; Rodrigues AP;
Infect Dis (Lond); 2022 Jun; 54(6):418-424. PubMed ID: 35023439
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil.
Chaves DG; Takahashi RHC; Campelo F; da Silva Malta MCF; de Oliveira IR; Barbosa-Stancioli EF; Ribeiro MA; Martins ML
Emerg Infect Dis; 2022 Apr; 28(4):734-742. PubMed ID: 35180375
[TBL] [Abstract][Full Text] [Related]
9. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
[TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
Front Public Health; 2022; 10():967447. PubMed ID: 36276377
[TBL] [Abstract][Full Text] [Related]
12. High Prevalence of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (Anti-SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey.
Nkuba AN; Makiala SM; Guichet E; Tshiminyi PM; Bazitama YM; Yambayamba MK; Kazenza BM; Kabeya TM; Matungulu EB; Baketana LK; Mitongo NM; Thaurignac G; Leendertz FH; Vanlerberghe V; Pelloquin R; Etard JF; Maman D; Mbala PK; Ayouba A; Peeters M; Muyembe JT; Delaporte E; Ahuka SM
Clin Infect Dis; 2022 Mar; 74(5):882-890. PubMed ID: 34089598
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.
Barchuk A; Shirokov D; Sergeeva M; Tursun Zade R; Dudkina O; Tychkova V; Barabanova L; Skougarevskiy D; Danilenko D
J Med Virol; 2021 Oct; 93(10):5846-5852. PubMed ID: 34081328
[TBL] [Abstract][Full Text] [Related]
14. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
15. The seroprevalence of SARS-CoV-2 in a rural southwest community.
Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study.
Moshe M; Daunt A; Flower B; Simmons B; Brown JC; Frise R; Penn R; Kugathasan R; Petersen C; Stockmann H; Ashby D; Riley S; Atchison C; Taylor GP; Satkunarajah S; Naar L; Klaber R; Badhan A; Rosadas C; Marchesin F; Fernandez N; Sureda-Vives M; Cheeseman H; O'Hara J; Shattock R; Fontana G; Pallett SJC; Rayment M; Jones R; Moore LSP; Ashrafian H; Cherapanov P; Tedder R; McClure M; Ward H; Darzi A; Elliott P; Cooke GS; Barclay WS;
BMJ; 2021 Mar; 372():n423. PubMed ID: 33653694
[TBL] [Abstract][Full Text] [Related]
17. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.
Biggs HM; Harris JB; Breakwell L; Dahlgren FS; Abedi GR; Szablewski CM; Drobeniuc J; Bustamante ND; Almendares O; Schnall AH; Gilani Z; Smith T; Gieraltowski L; Johnson JA; Bajema KL; McDavid K; Schafer IJ; Sullivan V; Punkova L; Tejada-Strop A; Amiling R; Mattison CP; Cortese MM; Ford SE; Paxton LA; Drenzek C; Tate JE;
MMWR Morb Mortal Wkly Rep; 2020 Jul; 69(29):965-970. PubMed ID: 32701941
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.
Spinelli MA; Lynch KL; Yun C; Glidden DV; Peluso MJ; Henrich TJ; Gandhi M; Brown LB
Lancet HIV; 2021 Jun; 8(6):e334-e341. PubMed ID: 33933189
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
[TBL] [Abstract][Full Text] [Related]
20. Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample.
Han J; Baek HJ; Noh E; Yoon K; Kim JA; Ryu S; Lee KO; Park NY; Jung E; Kim S; Lee H; Hwang YS; Jung J; Lee HJ; Cho SI; Oh S; Kim M; Oh CM; Yu B; Hong YS; Kim K; Jung SJ; Han MA; Lee MS; Lee JJ; Hwangbo Y; Yim HW; Kim YM; Lee J; Lee WY; Park JH; Oh S; Jo HS; Kim H; Kang G; Nam HS; Lee JH; Oh GJ; Shin MH; Ryu S; Hwang TY; Park SW; Kim SK; Seol R; Park KS; Kim SY; Kwon JW; Kim SS; Kim B; Lee JW; Jang EY; Kim AR; Nam J; ; Lee SY; Kim DH
Epidemiol Health; 2023; 45():e2023075. PubMed ID: 37591786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
